Clinical

Dataset Information

0

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity


ABSTRACT: Primary Objective: To assess the benefit of glutamine when added to calcium-magnesium on the occurrence of grade 2, 3 and 4 peripheral sensory neuropathy (PSN) related to oxaliplatin with the National Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) scale taking into account the time from start of oxaliplatin at which the first event occurred. Secondary Objective: To determine cumulative dose of oxaliplatin and time when the first occurrence of grade 2, 3 or 4 PSN. To determine the incidence of dose-reductions, dose-delays and discontinuations of oxaliplatin due to PSN grade 3 or 4. To assess effects of glutamine when added to calcium-magnesium on patients-reported outcomes using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 12 items questionnaire (FACT/GOG NTX-12) subscale. To evaluate the incidence of diarrhea. To determine Progression Free Survival (PFS) in metastatic patients.

DISEASE(S): Neurotoxicity Syndromes,Colorectal Neoplasms

PROVIDER: 2086375 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2087278 | ecrin-mdr-crc
| 2028254 | ecrin-mdr-crc
| 2157857 | ecrin-mdr-crc
| PRJNA189046 | ENA
2020-03-11 | GSE146739 | GEO
2015-04-07 | GSE54844 | GEO
| 2684595 | ecrin-mdr-crc
2023-12-11 | GSE233427 | GEO
2014-05-21 | GSE44185 | GEO
2023-03-11 | PXD037286 | Pride